Home LiteratureArticle Details
PMID: 9797205 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Antimicrobial agents and chemotherapy ·Vol. 42 ·No. 11 ·1998-11-00 ·Pages 2792-8

González I, Georgiou M, Alcaide F, Balas D, Liñares J, de la Campa AG

Abstract

The nucleotide sequences of the quinolone resistance-determining regions (QRDRs) of the parC and gyrA genes from seven ciprofloxacin-resistant (Cpr) isolates of viridans group streptococci (two high-level Cpr Streptococcus oralis and five low-level Cpr Streptococcus mitis isolates) were determined and compared with those obtained from susceptible isolates. The nucleotide sequences of the QRDRs of the parE and gyrB genes from the five low-level Cpr S. mitis isolates and from the NCTC 12261 type strain were also analyzed. Four of these low-level Cpr isolates had changes affecting the subunits of DNA topoisomerase IV: three in Ser-79 (to Phe or Ile) of ParC and one in ParE at a position not previously described to be involved in quinolone resistance (Pro-424). One isolate did not show any mutation. The two high-level Cpr S. oralis isolates showed mutations affecting equivalent residue positions of ParC and GyrA, namely, Ser-79 to Phe and Ser-81 to Phe or Tyr, respectively. The parC mutations were able to transform Streptococcus pneumoniae to ciprofloxacin resistance, while the gyrA mutations transformed S. pneumoniae only when mutations in parC were present. These results suggest that DNA topoisomerase IV is a primary target of ciprofloxacin in viridans group streptococci, DNA gyrase being a secondary target.

MeSH Terms
Amino Acid Sequence Anti-Infective Agents/pharmacology Base Sequence Ciprofloxacin/pharmacology DNA Gyrase DNA Topoisomerase IV DNA Topoisomerases, Type II/drug effects,genetics Drug Resistance, Microbial Genes, Bacterial Humans Molecular Sequence Data Mutation Polymerase Chain Reaction Streptococcus/drug effects,genetics Transformation, Genetic
Chemicals
Anti-Infective Agents Ciprofloxacin DNA Topoisomerase IV DNA Gyrase DNA Topoisomerases, Type II
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
González I
Unidad de Genética Bacteriana (Consejo Superior de Investigaciones Científicas), Centro Nacional de Biología Fundamental, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.
Georgiou M
Alcaide F
Balas D
Liñares J
de la Campa A G
References (37)
37 references, click to expand
  1. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801-5 PMID: 8524852
  2. Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae.
    J Bacteriol. 1998 Jun;180(11):2854-61 PMID: 9603872
  3. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    J Bacteriol. 1996 Jul;178(14):4060-9 PMID: 8763932
  4. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC.
    Antimicrob Agents Chemother. 1996 Jul;40(7):1741-4 PMID: 8807076
  5. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.
    Antimicrob Agents Chemother. 1996 Sep;40(9):2117-20 PMID: 8878591
  6. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7 PMID: 8891124
  7. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
    Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6 PMID: 8891138
  8. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10 PMID: 8913454
  9. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
    Antimicrob Agents Chemother. 1996 Dec;40(12):2760-4 PMID: 9124836
  10. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.
    Antimicrob Agents Chemother. 1997 Jan;41(1):175-9 PMID: 8980775
  11. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Antimicrob Agents Chemother. 1997 Feb;41(2):471-4 PMID: 9021211
  12. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.
    Antimicrob Agents Chemother. 1997 May;41(5):1166-7 PMID: 9145891
  13. Cellular metabolism in genetic transformation of pneumococci: requirement for protein synthesis during induction of competence.
    J Bacteriol. 1970 Mar;101(3):860-71 PMID: 4392399
  14. Facilitation of plasmid transfer in Streptococcus pneumoniae by chromosomal homology.
    J Bacteriol. 1982 May;150(2):692-701 PMID: 6279568
  15. DNA topoisomerases.
    Annu Rev Biochem. 1985;54:665-97 PMID: 2992360
  16. Characterization of genetic transformation in Streptococcus oralis NCTC 11427: expression of the pneumococcal amidase in S. oralis using a new shuttle vector.
    Mol Gen Genet. 1988 Dec;215(1):53-7 PMID: 3241622
  17. Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.
    Antimicrob Agents Chemother. 1989 Apr;33(4):580-2 PMID: 2729950
  18. Classification and identification of the viridans streptococci.
    Clin Microbiol Rev. 1989 Jul;2(3):315-28 PMID: 2670193
  19. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
    Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2 PMID: 2168148
  20. Sequence of the Streptococcus pneumoniae bacteriophage HB-3 amidase reveals high homology with the major host autolysin.
    J Bacteriol. 1990 Sep;172(9):5064-70 PMID: 1975580
  21. New topoisomerase essential for chromosome segregation in E. coli.
    Cell. 1990 Oct 19;63(2):393-404 PMID: 2170028
  22. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
    Antimicrob Agents Chemother. 1991 Aug;35(8):1647-50 PMID: 1656869
  23. Resistance to antibiotics mediated by target alterations.
    Science. 1994 Apr 15;264(5157):388-93 PMID: 8153626
  24. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.
    Clin Infect Dis. 1994 Jan;18(1):25-31 PMID: 8054434
  25. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Mol Microbiol. 1994 Aug;13(4):641-53 PMID: 7997176
  26. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
    Antimicrob Agents Chemother. 1994 Sep;38(9):2014-23 PMID: 7811012
  27. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.
    Antimicrob Agents Chemother. 1994 Sep;38(9):2091-4 PMID: 7811024
  28. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.
    Mol Microbiol. 1994 Oct;14(2):371-80 PMID: 7830580
  29. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
    Antimicrob Agents Chemother. 1994 Nov;38(11):2623-7 PMID: 7872758
  30. The twisted 'life' of DNA in the cell: bacterial topoisomerases.
    Mol Microbiol. 1995 Feb;15(4):601-6 PMID: 7783632
  31. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance.
    J Bacteriol. 1995 Jul;177(14):4166-70 PMID: 7608096
  32. Comparison of phenotypic characteristics, DNA-DNA hybridization results, and results with a commercial rapid biochemical and enzymatic reaction system for identification of viridans group streptococci.
    J Clin Microbiol. 1995 May;33(5):1215-22 PMID: 7615731
  33. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.
    Clin Infect Dis. 1995 May;20(5):1169-73 PMID: 7619995
  34. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
    FEMS Microbiol Lett. 1995 Oct 1;132(1-2):57-60 PMID: 7590165
  35. Nomenclature for aerobic and facultative bacteria.
    Clin Infect Dis. 1997 Jul;25(1):1-10 PMID: 9243023
  36. Whole-cell protein electrophoretic analysis of viridans streptococci: evidence for heterogeneity among Streptococcus mitis biovars.
    Int J Syst Bacteriol. 1998 Jan;48 Pt 1:117-25 PMID: 9542082
  37. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood.
    Antimicrob Agents Chemother. 1995 Oct;39(10):2243-7 PMID: 8619576
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1998-11-00
Pages
2792-8
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC105945
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com